Optimizing dose-schedule regimens with bayesian adaptive designs: opportunities and challenges.

ABSTRACT: Due to the small sample sizes in early-phase clinical trials, the toxicity and efficacy profiles of the dose-schedule regimens determined for subsequent trials may not be well established. The recent development of novel anti-tumor treatments and combination therapies further complicates the problem. Therefore, there is an increasing recognition of the essential place of optimizing dose-schedule regimens, and new strategies are now urgently needed. Bayesian adaptive designs provide a potentially effective way to evaluate several doses and schedules simultaneously in a single clinical trial with higher efficiency, but real-world implementation examples of such adaptive designs are still few. In this paper, we cover the critical factors associated with dose-schedule optimization and review t

SUBMITTER: Chen X 

PROVIDER: S-EPMC10701540 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature